130 related articles for article (PubMed ID: 32977662)
21. Prognostic utility of neutrophil-to-lymphocyte and platelets-to-lymphocyte ratio in predicting biochemical recurrence post robotic prostatectomy.
Zanaty M; Ajib K; Alnazari M; El Rassy E; Aoun F; Zorn KC; El-Hakim A
Biomark Med; 2018 Aug; 12(8):841-848. PubMed ID: 30019909
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
[TBL] [Abstract][Full Text] [Related]
23. Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
Matzkin H; Chen J; Agai R; Ziv-Baran T; Mabjeesh NJ
PLoS One; 2019; 14(4):e0215582. PubMed ID: 31002732
[TBL] [Abstract][Full Text] [Related]
24. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
25. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
26. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
27. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
28. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
29. Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy.
Niwa N; Matsumoto K; Nishiyama T; Yagi Y; Ozu C; Nakamura K; Saito S; Oya M
Brachytherapy; 2018; 17(6):899-905. PubMed ID: 30245170
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
Keizman D; Gottfried M; Ish-Shalom M; Maimon N; Peer A; Neumann A; Rosenbaum E; Kovel S; Pili R; Sinibaldi V; Carducci MA; Hammers H; Eisenberger MA; Sella A
Oncologist; 2012; 17(12):1508-14. PubMed ID: 22971522
[TBL] [Abstract][Full Text] [Related]
31. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
[TBL] [Abstract][Full Text] [Related]
32. Preoperative Predictors of Biochemical Recurrence-Free Survival in High-Risk Prostate Cancer Following Radical Prostatectomy.
Nkengurutse G; Tian F; Jiang S; Wang Q; Wang Y; Sun W
Front Oncol; 2020; 10():1761. PubMed ID: 33014867
[No Abstract] [Full Text] [Related]
33. Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers.
Meynard C; Huertas A; Dariane C; Toublanc S; Dubourg Q; Urien S; Timsit MO; Méjean A; Thiounn N; Giraud P
Radiat Oncol; 2019 Dec; 15(1):1. PubMed ID: 31892338
[TBL] [Abstract][Full Text] [Related]
34. Intraprostatic calcification and biochemical recurrence in men treated with cesium-131 prostate brachytherapy.
Schad MD; Rodríguez-López JL; Patel AK; Houser CJ; Horne ZD; Benoit RM; Smith RP; Beriwal S
Brachytherapy; 2021; 20(4):859-865. PubMed ID: 33994343
[TBL] [Abstract][Full Text] [Related]
35. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
36. Validation of the Effectiveness of Neutrophil-to-lymphocyte Ratio (NLR) as a Predictive Factor in Patients Undergoing Prostate Biopsy With Prostate Specific Antigen (PSA) Between 4.0 and 10.0 ng/ml.
Masuda H; Mikami K; Otsuka K; Hou K; Suyama T; Araki K; Kojima S; Naya Y
In Vivo; 2021; 35(3):1641-1646. PubMed ID: 33910847
[TBL] [Abstract][Full Text] [Related]
37. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
38. The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancer.
Sagalovich D; Leapman M; Sfakianos J; Hall S; Stock R; Stone N
Brachytherapy; 2016; 15(6):730-735. PubMed ID: 27743956
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy.
Kawahara T; Fukui S; Sakamaki K; Ito Y; Ito H; Kobayashi N; Izumi K; Yokomizo Y; Miyoshi Y; Makiyama K; Nakaigawa N; Yamanaka T; Yao M; Miyamoto H; Uemura H
Oncotarget; 2015 Oct; 6(31):32169-76. PubMed ID: 26359354
[TBL] [Abstract][Full Text] [Related]
40. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
